Cancer Family
Reproductive System Neoplasm
CI-CAN-00000338Explore in graph →
Non-malignant3,042 active trials38 approved drugs197 evidence items
- NCIt
- C3674
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000338Explore in graph →
Clinical trials
13,672 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01012141 | Docetaxel With a Phytochemical in Treating Patients With Hormone Independent Metastatic Prostate Cancer(PROTAXY) | completed | Phase 2 | 30 | Centre Jean PerrinOTHER | 1 | Apr 10, 2013 | clinicaltrials |
| NCT00003626 | Dolastatin 10 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Previous Hormone Therapy | completed | Phase 2 | — | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Apr 5, 2013 |
| clinicaltrials |
| NCT00243048 | Isoflavones and Radiation Therapy in Treating Patients With Localized Prostate Cancer | completed | Phase 2 | 70 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Apr 5, 2013 | clinicaltrials |
| NCT01825642 | Prospective Randomized Trial of Seminal Vesicle-Sparing Prostatectomy and Nerve-Sparing Radical Prostatectomy in Men With Clinically Localized Prostate Cancer | completed | Phase 2 / Phase 3 | 140 | University of MichiganOTHER | 1 | Apr 5, 2013 | clinicaltrials |
| NCT00046826 | Docetaxel, Estramustine, and Thalidomide in Treating Patients With Prostate Cancer Previously Treated With Hormone Therapy | completed | Phase 2 | — | Nuvance HealthOTHER | 1 | Apr 4, 2013 | clinicaltrials |
| NCT00003408 | Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Cancer | completed | Phase 2 | 40 | Cancer Treatment Centers of AmericaOTHER | 1 | Mar 26, 2013 | clinicaltrials |
| NCT00026091 | Fenretinide in Treating Patients With Recurrent or Metastatic Ovarian Epithelial or Primary Peritoneal Cancer | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Mar 25, 2013 | clinicaltrials |
| NCT00004211 | Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer | completed | Phase 1 / Phase 2 | 17 | Duke UniversityOTHER | 1 | Mar 21, 2013 | clinicaltrials |
| NCT00244998 | Fulvestrant in Treating Patients With Advanced Prostate Cancer | completed | Phase 2 | 20 | Roswell Park Cancer InstituteOTHER | 1 | Mar 8, 2013 | clinicaltrials |
| NCT00003173 | High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid Tumors | completed | Phase 2 | 36 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 7, 2013 | clinicaltrials |
| NCT00004066 | Gemcitabine, Docetaxel, and Filgrastim in Treating Patients With Recurrent or Persistent Leiomyosarcoma or Soft Tissue Sarcoma | completed | Phase 2 | 82 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 7, 2013 | clinicaltrials |
| NCT00103337 | Cilengitide in Treating Patients With Metastatic Prostate Cancer | completed | Phase 2 | 106 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2013 | clinicaltrials |
| NCT00041041 | Imatinib Mesylate in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal Cancer | completed | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Feb 20, 2013 | clinicaltrials |
| NCT00757692 | Efficacy and Safety Study of Vandetanib (ZD 6474) in Combination With Bicalutamide Versus Bicalutamide Alone in Patients With Chemotherapy Naive Hormone Refractory Prostate Cancer. | completed | Phase 2 | 74 | British Columbia Cancer AgencyOTHER | 1 | Feb 20, 2013 | clinicaltrials |
| NCT01303328 | Safety and Efficacy Study of Antiviral Local Application to Treat High Grade Cervical Intraepithelial Lesions (CIN2/3)(Colvir-PhaseII) | completed | Phase 2 | 200 | Mithra PharmaceuticalsINDUSTRY | 1 | Feb 18, 2013 | clinicaltrials |
| NCT00003136 | Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Epithelial Ovarian Cancer or Primary Peritoneal Cancer | completed | Phase 1 / Phase 2 | 11 | University of ChicagoOTHER | 1 | Feb 11, 2013 | clinicaltrials |
| NCT00003256 | Flavopiridol in Treating Patients With Recurrent Prostate Cancer | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Feb 11, 2013 | clinicaltrials |
| NCT00027599 | APC8015 and Bevacizumab in Treating Patients With Prostate Cancer | completed | Phase 2 | 25 | National Cancer Institute (NCI)NIH | 1 | Feb 11, 2013 | clinicaltrials |
| NCT00003778 | Dolastatin 10 in Treating Patients With Recurrent or Metastatic Soft Tissue Sarcoma | completed | Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | Feb 8, 2013 | clinicaltrials |
| NCT00257348 | Capecitabine and Docetaxel in Advanced/Recurrent Cervical Cancer | completed | Phase 2 | 5 | University of California, IrvineOTHER | 1 | Feb 8, 2013 | clinicaltrials |
| NCT00962494 | Cancer: Thriving and Surviving Online Workshop and Study for Cancer Survivors | completed | Phase 2 | 585 | Stanford UniversityOTHER | 2 | Feb 7, 2013 | clinicaltrials |
| NCT00265070 | Trial of Iressa in Prostate Cancer Patients | completed | Phase 2 | 80 | AstraZenecaINDUSTRY | 1 | Feb 5, 2013 | clinicaltrials |
| NCT00433446 | S0354, Anti-IL-6 Chimeric Monoclonal Antibody in Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy | completed | Phase 2 | 62 | SWOG Cancer Research NetworkNETWORK | 1 | Feb 5, 2013 | clinicaltrials |
| NCT00040755 | BMS-275291 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy | completed | Phase 2 | 68 | National Cancer Institute (NCI)NIH | 1 | Feb 1, 2013 | clinicaltrials |
| NCT00276549 | Gemcitabine and Docetaxel in Treating Patients With Metastatic Prostate Cancer | completed | Phase 2 | 35 | Case Comprehensive Cancer CenterOTHER | 1 | Jan 31, 2013 | clinicaltrials |
| NCT00939510 | Lenalidomide and GM-CSF in Treating Patients With Prostate Cancer | completed | Phase 1 / Phase 2 | 32 | Robert Dreicer MDOTHER | 1 | Jan 31, 2013 | clinicaltrials |
| NCT00003832 | Broxuridine Plus Surgery in Treating Patients With Stage I or Stage II Prostate Cancer | completed | Phase 2 | 75 | National Cancer Institute (NCI)NIH | 1 | Jan 25, 2013 | clinicaltrials |
| NCT00096499 | SB-715992 in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Docetaxel or Paclitaxel | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Jan 25, 2013 | clinicaltrials |
| NCT00025467 | Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer | completed | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00036751 | Imatinib Mesylate in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00054041 | Vaccine Therapy in Preventing Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia | completed | Phase 2 | 84 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00074022 | GTI-2040 and Docetaxel in Treating Patients With Recurrent, Metastatic, or Unresectable Locally Advanced Non-Small Cell Lung Cancer, Prostate Cancer, or Other Solid Tumors | completed | Phase 1 / Phase 2 | 48 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00081276 | 3-AP and Cisplatin in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer | completed | Phase 2 | 48 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00083928 | Efficacy of Å6 in Ovarian Cancer Patients Following First-Line Chemotherapy and a Rising CA125 Levels | completed | Phase 2 | 60 | Ångstrom PharmaceuticalsINDUSTRY | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00016289 | Interleukin-12 in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer | completed | Phase 2 | 30 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00109811 | Vaccine Therapy in Treating Patients With Recurrent Prostate Cancer | completed | Phase 2 | 32 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT01452659 | Efficacy and Safety of TAK-385 in the Treatment of Uterine Fibroids | completed | Phase 2 | 216 | TakedaINDUSTRY | 1 | Jan 21, 2013 | clinicaltrials |
| NCT00020891 | CT Scans in Guiding the Treatment of Patients With Prostate Cancer Who Are Undergoing Radiation Therapy | completed | Phase 2 | 25 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 18, 2013 | clinicaltrials |
| NCT00147212 | ET 743 (Yondelis) in Men With Advanced Prostate Cancer | completed | Phase 2 | 50 | Massachusetts General HospitalOTHER | 1 | Jan 18, 2013 | clinicaltrials |
| NCT00289341 | Safety and Effectiveness of a Vaccine for Prostate Cancer That Uses Each Patients' Own Immune Cells. | completed | Phase 1 / Phase 2 | 24 | Rockefeller UniversityOTHER | 1 | Jan 18, 2013 | clinicaltrials |
| NCT00635193 | Efficacy and Safety Study of M200(Volociximab in Combination With Liposomal Doxorubicin) | completed | Phase 1 / Phase 2 | 138 | AbbVie (prior sponsor, Abbott)INDUSTRY | 9 | Jan 18, 2013 | clinicaltrials |
| NCT00738673 | Degarelix as Second-Line Hormonal Treatment After Prostate-specific Antigen (PSA)-Failure in GnRH Agonist Treated Patients With Prostate Cancer | completed | Phase 2 | 37 | Ferring PharmaceuticalsINDUSTRY | 1 | Jan 18, 2013 | clinicaltrials |
| NCT00031993 | Erlotinib in Treating Patients With Persistent or Recurrent Cancer of the Cervix | completed | Phase 2 | 51 | National Cancer Institute (NCI)NIH | 1 | Jan 17, 2013 | clinicaltrials |
| NCT00014352 | Combination Chemotherapy Plus Warfarin in Treating Patients With Prostate Cancer | completed | Phase 2 | — | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00059943 | Docetaxel in Treating Older Patients With Metastatic Breast, Lung, or Prostate Cancer | completed | Phase 2 | — | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00107445 | EF5 in Finding Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Cervical, Endometrial, or Ovarian Epithelial Cancer | completed | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00050414 | A Study of Trabectedin in Patients With Advanced Ovarian Cancer | completed | Phase 2 | 147 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C.INDUSTRY | 0 | Jan 10, 2013 | clinicaltrials |
| NCT00396591 | AVE0005 (VEGF Trap) in Patients With Recurrent Symptomatic Malignant Ascites | completed | Phase 2 | 16 | SanofiINDUSTRY | 3 | Jan 10, 2013 | clinicaltrials |
| NCT00063895 | Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer, Ovarian Cancer, or Squamous Cell Carcinoma of the Head and Neck | completed | Phase 1 / Phase 2 | 80 | National Cancer Institute (NCI)NIH | 1 | Jan 9, 2013 | clinicaltrials |
| NCT00050440 | Phase 2 Study of ET-743 (Trabectedin) in Patients With Persistent or Recurrent Endometrial Carcinoma | completed | Phase 2 | 50 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C.INDUSTRY | 4 | Jan 8, 2013 | clinicaltrials |
Data updated 23 days agoSource updated Apr 10, 2013source: clinicaltrials